

Title

Association of known melanoma risk factors with primary melanoma of the scalp and neck

Authors

Renee P Wood¹, Jane S Heyworth¹, Nina S McCarthy², Audrey Mauguen³, Marianne Berwick⁴, Nancy E Thomas⁵, Michael J Millward⁶, Hoda Anton-Culver⁷, Anne E Cust⁸, Terence Dwyer^{9,10}, Richard P Gallagher¹¹, Stephen B Gruber¹², Peter A Kanetsky¹³, Irene Orlov³, Stefano Rosso¹⁴, Eric K Moses¹⁵, Colin B Begg³, Sarah V Ward^{1,3}

Affiliations

¹ *School of Population and Global Health, The University of Western Australia, Perth, Western Australia, Australia*

² *School of Biomedical Sciences, The University of Western Australia, Perth, Western Australia, Australia*

³ *Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA*

⁴ *Department of Internal Medicine, University of New Mexico Cancer Center, University of New Mexico, Albuquerque, New Mexico, USA*

⁵ *Department of Dermatology, School of Medicine and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA*

⁶ *Medical School, The University of Western Australia, Perth, Western Australia, Australia*

⁷ *Department of Medicine, University of California, Irvine, California, USA*

⁸ *Sydney School of Public Health and The Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia*

⁹ *George Institute for Global Health Research, University of Oxford, Oxford, UK*

¹⁰ *Murdoch Children's Research Institute, Melbourne, Victoria, Australia*

¹¹ *British Columbia Cancer Research Centre and Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada*

¹² *Department of Medical Oncology, City of Hope National Medical Center, Duarte, California, USA*

¹³ *Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA*

¹⁴ *Piedmont Cancer Registry, Turin, Italy*

¹⁵*Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.*

Running title

Factors associated with scalp and neck melanoma

Abbreviations list

CCND1: Cyclin D1

CI: Confidence intervals

GEM: Genes, Environment and Melanoma Study

ICD-O3: International Classification of Disease for Oncology

IRF4: Interferon regulatory factor-4

OR: Odds ratio

SN: Scalp and neck

SNP: Single nucleotide polymorphism

WAMHS: Western Australian Melanoma Health Study

Corresponding author

Sarah Ward

School of Population and Global Health

The University of Western Australia

M431, 35 Stirling Highway

Crawley WA 6009

Email: sarah.ward@uwa.edu.au

Conflict of interest disclosure statement

SB Gruber is the Co-Founder of Brogent International LLC. No other authors have potential conflicts to declare.

ABSTRACT

Background: Scalp and neck (SN) melanoma confers a worse prognosis than melanoma of other sites but little is known about its determinants. We aimed to identify associations between SN melanoma and known risk genes, phenotypic traits and sun exposure patterns.

Methods: Participants were cases from the Western Australian Melanoma Health Study (n=1,200) and the Genes, Environment and Melanoma Study (n=3,280). Associations between risk factors and SN melanoma, compared with truncal and arm/leg melanoma, were investigated using binomial logistic regression. Facial melanoma was also compared with the trunk and extremities, to evaluate whether associations were sub-region specific, or reflective of the whole head/neck region.

Results: Compared with other sites, increased odds of SN and facial melanoma were observed in older individuals (SN: OR=1.28, 95% CI=0.92–1.80, $P_{\text{trend}}=0.016$; Face: OR=4.57, 95% CI=3.34–6.35, $P_{\text{trend}}<0.001$) and those carrying *IRF4*-rs12203592*T (SN: OR=1.35, 95% CI=1.12–1.63, $P_{\text{trend}}=0.002$; Face: OR=1.29, 95% CI=1.10–1.50, $P_{\text{trend}}=0.001$). Decreased odds were observed for females (SN: OR=0.49, 95% CI=0.37–0.64, $P<0.001$; Face: OR=0.66, 95% CI=0.53–0.82, $P<0.001$) and the presence of nevi (SN: OR=0.66, 95% CI=0.49–0.89, $P=0.006$; Face: OR=0.65, 95% CI=0.52–0.83, $P<0.001$).

Conclusions: Differences observed between SN melanoma and other sites were also observed for facial melanoma. Factors previously associated with the broader head and neck region, notably older age, may be driven by the facial sub-region. A novel finding was the association of *IRF4*-rs12203592 with both SN and facial melanoma.

Impact: Understanding the epidemiology of site-specific melanoma will enable tailored strategies for risk factor reduction and site-specific screening campaigns.

INTRODUCTION

Cutaneous malignant melanoma is a major public health issue, particularly in light-skinned populations. It is a complex cancer thought to arise from multiple genetic and environmental factors and their interactions, and it also exhibits a site-specific pattern of development (1, 2). Most current research has focused on the head and neck, upper limbs, lower limbs and the trunk as broad anatomic sites of interest. The head and neck region is of particular interest, as while it accounts for 9.0% of the body's total surface area, melanoma tumors in the region account for 12.0- 26.0% of total melanoma incidence (3, 4). They also have a poorer prognosis compared with melanomas arising on other sites of the body, with reported five-year survival rates of 78.9% compared with 93.1% (4, 5). Further prognostic differences have been observed within the head and neck region. Studies have consistently shown a worse prognosis for scalp and neck (SN) melanomas compared with melanoma of other sites (including other head and neck sites), with lower five- and ten-year survival rates and a higher incidence of melanoma-specific mortality (4, 6-9). Several histopathologic factors, such as tumour thickness and the presence of ulceration, have been associated with poorer prognosis in SN melanoma but these do not account for all of the variation seen in survival rates and prognosis between melanoma in this region and other anatomic sites (10, 11).

SN melanoma is therefore an important subset of melanoma and further investigation is required to better understand the underlying biology and determinants of melanoma at this site. Identifying risk factors associated with SN melanoma will also inform strategies for tailoring risk prevention in those at greater risk of this subset of melanoma. To date, most research into the individual and environmental determinants of anatomic site of melanoma development has focused on the broader anatomic regions. The limited research into risk factors specifically associated with SN melanoma has shown that it occurs more frequently in males than females, and in comparison to melanoma of all other sites, often occurs at an older age (4, 6). There is also little known regarding genetic polymorphisms associated with site-specific melanoma development, including whether there is a genetic predisposition specifically to SN melanoma.

Therefore, the purpose of this study was to use data from two large population-based melanoma studies to determine whether the associations between demographic factors, known melanoma susceptibility traits, environmental exposures and genetic polymorphisms differed between SN melanoma and other anatomic sites. Facial melanoma was considered separately to enable us

to discern whether any observed associations were specific to SN melanoma, or more reflective of an association with melanoma of the broader head and neck region.

MATERIALS AND METHODS

Study design and sample

Two independent population-based collections of primary melanoma cases were used, the Western Australian Melanoma Health Study (WAMHS) and the Genes, Environment and Melanoma (GEM) study. Analyses to investigate the association between known melanoma risk factors and anatomic site were conducted as pooled analyses, using both the WAMHS and GEM cases.

Both study populations have previously been described in detail (12, 13). Briefly, the WAMHS consists of 1643 consenting participants, who were diagnosed with primary, invasive melanoma between the ages of 18 and 80 years. All participants were recruited from the Western Australian Cancer registry between 2006 and 2009. There were 1215 individuals with both questionnaire and genetic data available and after excluding those with missing anatomic site data (n=4) and missing or non-European ancestry (n=11), there were 1200 WAMHS individuals available for analyses.

The GEM study is an international, multi-centre study, consisting of 3579 melanoma cases, who were recruited as either single primary melanoma cases (first invasive, primary melanoma) or multiple primary melanoma cases (second or higher-order primary melanoma, either invasive or *in situ*). Participants were recruited from 2000 to 2003 from eight population-based cancer registries and one hospital centre in four countries: Australia, Canada, Italy and the United States of America. Our analyses included only the primary melanoma that was used for recruitment into the study for both single and multiple primary cases. Cases without the relevant genetic single nucleotide polymorphism (SNP) data (n=16), unspecified head and neck site data (n=11), non-European ancestry (n=12) and *in situ* melanoma (n=274) were excluded (not mutually exclusive). This resulted in 3280 GEM cases and a total of 4480 melanoma cases from both studies that were available for the pooled analyses.

Ethics Approval

Ethical approval was obtained from each study site's institutional review board for all data collection and subsequent analyses, and written informed consent was obtained from all participants.

Assessment of anatomic site

Anatomic site was defined by International Classification of Disease for Oncology 3rd Edition (ICD-O-3) topography codes for the skin (C440 – C449) (14). The dependent variables for analysis were categorical variables of SN melanoma *vs.* melanoma of the trunk and extremities, and facial melanoma *vs.* melanoma of the trunk and extremities. SN melanoma was classified by ICD O-3 code C444 and facial melanomas were classified by ICD O-3 codes C440, C441, C442 and C443, which included melanoma of the lip, eyelid, ear and other parts of the face. Histopathology data were obtained from pathology reports for WAMHS participants and by pathologist review for GEM participants.

Demographic, phenotypic and sun exposure data

All demographic, phenotypic trait and sun exposure variables were derived from the harmonisation of the WAMHS and GEM questionnaire data. Comparable self-reported data had previously been collected by both studies, using questionnaires that were administered by telephone interview. Synonymous definitions were created for each risk factor and identical inclusion and exclusion criteria were applied to all variables.

Demographic variables were sex and age at diagnosis. Phenotypic variables were the presence of nevi (based on pictures of four bodies showing different degrees of nevi coverage), freckles in childhood (based on six pictures showing degree of facial freckling), hair color, eye color and skin color. Propensity to burn and ability to tan were based on reported skin response to one hour of sun exposure at the beginning of summer and repeated exposure during summer, respectively. Categories were condensed into binary burn and tan indices for ease of analysis due to sample distribution, as were categories for freckling and naevi.

Environmental variables focused on sun exposure during the critical childhood and adolescence periods (15). For both time periods, the number of painful and blistering sunburns were used as proxy measures of intermittent exposure, and average weekday and weekend exposure between 9am – 5pm during the warmer months were used as measures of cumulative exposure. Whether patients had ever used a sunbed in their lifetime was also included.

Genetic data

We included known melanoma susceptibility SNPs that had previously been identified from the literature and genotyped prior to commencement of this study. There were 22 SNPs common to both the GEM and WAMHS data that were extracted for this study. The minor allele frequency was determined for each SNP and compared with the 1000 Genomes-CEU minor allele frequency (16) (Supplementary Table 1).

DNA samples from WAMHS participants were extracted from peripheral blood samples and genotyped on an Illumina OmniExpressExome-v1 chip (San Diego, CA, USA), using standard quality control procedures. DNA samples from GEM participants were collected from buccal brushes and SNPs were genotyped on the MassArray iPLEX platform (Agena Bioscience, formerly Sequenom, Inc., San Diego, CA, USA), using quality control measures previously reported (17).

Statistical analyses

Distributions of key participant characteristics in the pooled sample were summarised using means, standard deviations, frequencies and proportions. Logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for SN melanoma and facial melanoma, compared separately to other sites of melanoma. Models were adjusted for age at diagnosis, sex, study centre (each of the nine GEM collection sites plus WAMHS as the tenth site) and whether it was a first or higher order melanoma.

Candidate gene analyses used an additive genetic model and the same logistic regression model approach to estimate the per-allele (based on the minor allele) ORs and CIs for each SNP. Models were also adjusted for study features. The Monte-Carlo test (18) was used to adjust for multiple testing and take into account linkage disequilibrium between the 22 SNPs, with an estimated significance threshold of $P < 0.003$ determined. To check the appropriateness of pooling the data from the GEM and WAMHS studies, we conducted random-effects meta-analyses and tests of heterogeneity using the R package ‘metafor’ (19) for all variables with a statistically significant result. All analyses were undertaken using the software program R v.3.3.3 (20).

RESULTS

Study sample characteristics

The demographic and phenotypic characteristics of the final study sample are presented in Table 1. The sample comprised 293 cases of SN melanoma (6.5%), 460 cases of facial melanoma (10.3%) and 3727 cases of melanoma at other anatomic sites (trunk: n=1883 (42.0%), extremities: n=1844 (41.2%)). There were more males (56.2%) than females (43.8%), and the average age of diagnosis was 58.2 years (standard deviation=15.1 years).

Demographic, phenotypic and environmental risk factors

The associations of each variable with SN melanoma and facial melanoma, compared with other anatomic sites, are presented in Table 1 (demographic and phenotypic traits) and Table 2 (sun exposure). The strongest association observed was for sex, with female sex conferring a significantly decreased odds of developing both SN melanoma (OR=0.49, 95% CI=0.37–0.64) and facial melanoma (OR=0.66, 95% CI=0.53–0.82), compared with other sites. Age at diagnosis was also associated with both regions of the head and neck compared with other sites, although the pattern of association differed between the two sites. The odds of developing facial melanoma increased consistently with increasing age, with an OR of almost five observed in individuals more than 70 years of age (OR=4.57, 95% CI=3.34–6.35). On the other hand, a reduced odds of SN melanoma was observed for persons in the age group 50 to 59 years as compared with other ages.

The presence of nevi was associated with a reduced risk of melanoma at both anatomic sites (Face: OR=0.65, 95% CI=0.52–0.83; SN melanoma: OR=0.66, 95% CI=0.49–0.89). A significant association was observed between facial melanoma and hair colour but not with SN melanoma. Lighter (OR=0.79, 95% CI=0.64–0.98) and red hair (OR=0.65, 95% CI=0.42–0.97) conferred a decreased odds of developing facial melanoma, compared with dark hair. A greater number of painful (OR=0.73, 95% CI=0.58–0.92) and blistering sunburns (OR=0.72, 95% CI=0.56–0.92) in childhood were also each associated with decreased odds of facial melanoma. No significant associations were observed for any other pigmentary traits or environmental exposures.

Candidate gene associations

Prior to adjustment for multiple testing, the minor alleles of two SNPs were significantly associated with facial melanoma, and one with SN melanoma (Table 3). The minor T allele of rs12203592 in the interferon regulatory factor-4 (*IRF4*) gene was associated with an increased

odds of melanoma at both sites (Face: OR=1.29, 95% CI=1.10–1.50; SN melanoma: OR=1.35, 95% CI=1.12–1.63) and the T allele of rs11263498 in the cyclin D1 (*CCND1*) gene was associated with a decreased odds of facial melanoma (OR=0.81, 95% CI=0.70–0.94). Following adjustment for multiple testing, only rs12203592 (*IRF4*) passed the Monte-Carlo significance threshold ($P<0.003$) and remained significantly associated with both anatomic sites.

Meta-analyses

Tests of heterogeneity showed that the results for both SN and facial melanoma were generally very consistent between the GEM and WAMHS samples ($P>0.3$ for all variables), and the forest plots show that the confidence intervals for the results are highly overlapping between the GEM and WAMHS samples (Supplementary Figures 1 and 2). Together, these data indicate that since heterogeneity between the GEM and WAMHS results is low, a pooled data analysis was appropriate. Further, the direction of association in each of the separate GEM and WAMHS samples was the same as in the pooled analyses for each significant demographic, pigimentary and sun exposure variable (Supplementary Figures 1 and 2). The association between the *IRF4* SNP and SN melanoma in the smaller WAMHS sample suggested a reduced risk when rs12203592*T was present instead, although this association was close to the null (OR=0.92, 95% CI=0.64-1.29). All other associations with *IRF4* were observed in the same direction.

DISCUSSION

We identified several significant differences in risk factors between SN and facial melanoma, and melanoma of other anatomic sites. The decreased odds of both face and SN melanoma amongst females was the strongest association observed for both sites, and was consistent with previously observed patterns of sex-specific incidence across anatomic sites (21-23). A striking result was the substantial increase in the odds of developing facial melanoma, compared with other sites, with each decade after the age of 50 years. Although it has been widely reported that older individuals are more likely to develop head and neck melanoma in general (21, 24), it has not been shown previously that this association may be driven predominantly by the facial sub-region.

The inverse association we observed between lighter hair colour and facial melanoma was also novel. A previous meta-analysis found melanoma of sun exposed regions, including the arms and the entire head and neck region, to be associated with hair color (25). Our results suggest that this association may be primarily driven by the facial sub-region. Similarly, the likelihood of both SN melanoma and facial melanoma was reduced in the presence of nevi, compared with other sites, in line with previous study findings (25-28). We also observed a reduced odds of facial melanoma in individuals with a history of childhood sunburn, which is indicative of intermittent sun exposure.

Whilst previous studies have investigated genetic associations with the broader regions of the trunk and head/neck (5, 29, 30), we investigated for the first time whether there is a genetic predisposition specifically to SN melanoma and if it is biologically distinct from facial melanoma. We observed a significant increase in the odds of both SN melanoma and facial melanoma with each additional copy of the minor T allele of *IRF4* SNP rs12203592, a functional variant known to influence expression of the gene (31). These results are in line with a recent hospital-based study that observed a positive association between rs12203592*T and the development of all head and neck melanomas (30), and suggest that melanoma risk SNPs may play a role in the site-specific development of melanoma

The same T allele of the *IRF4* SNP has also previously been associated with various pigmentation traits, including associations with fewer nevi in adulthood and darker hair (32-35). The direction of association we observed between these phenotypic traits and anatomic site suggested the association could be driven by the rs12203592 C>T polymorphism. To assess the independence of our observed associations, we included rs12203592 in the phenotypic trait models but found no notable differences in results (Supplementary Table 2). Similarly, when the rs12203592 model was adjusted for each relevant phenotypic trait (nevi, freckling, hair colour, eye colour and ability to tan), no attenuation of results was observed (Supplementary Table 3). These results suggest that the observed genetic and pigmentary associations are independent from one another

Our observations for nevi and sun exposure are also consistent with the divergent pathway model for melanoma (27). There is growing evidence in the literature for the existence of two distinct pathways to melanoma development. One is driven by high levels of cumulative sun exposure and characterised by melanoma on sun-exposed sites, such as the head and neck, and

solar elastoses as a histological marker. The other is driven by a high propensity for nevus development and characterised by melanoma on less exposed sites and the presence of neval remnants histologically (24, 27, 36, 37). In line with this model, our findings for SNP rs12203592 are also consistent with a recent GEM study that found rs12203592*T was positively associated with melanoma tumors that had solar elastoses present, and inversely associated with tumors that had neval remnants (37).

Lentigo maligna melanoma is known to occur primarily on the head and neck, especially in older males with sun-damaged skin (3, 38, 39). Therefore, we also performed additional analyses to assess the potential effect of histology on the results. Models for significantly associated variables were adjusted for histology (lentigo maligna melanoma vs. other subtypes) but no difference in results was observed for phenotypic traits before and after adjustment for histology (Supplementary Table 4). The estimated odds ratios were attenuated for age for both face and SN melanoma, and the associations between facial melanoma and sun exposure became only marginally significant when adjusted for histology. These results suggest that the association between anatomic site and both age and sun exposure may be mediated by histologic subtype.

Limitations of the study included the use of self-reported risk factor information that may have been subject to recall bias and the use of two slightly different study questionnaires. Although our rigorous method of data harmonisation minimised major discrepancies between the datasets, an inherent limitation of pooled studies is that some variables are not available in both study samples and this therefore constrained some analyses. This included the absence of validated tools for assessing skin color, tumor staging data, detailed sun exposure history and a subset of known risk SNPs. To address this issue, substitute or proxy variables that were available in both studies were used instead where possible. For example, the use of self-reported skin color as the best available measure, and the use of sunburn as a proxy measure of intermittent sun exposure, as previously suggested in the literature (40). The key strengths of this study were the population-based study design and the use of two large and well characterised studies with comparable data. This facilitated a robust, pooled study design and made it the largest study to date to investigate the genetic and non-genetic factors associated with SN melanoma.

In summary, our investigation found that known melanoma risk factors may not play a role in distinguishing the profile of SN melanoma. All risk factors associated with SN melanoma, compared with melanoma of other anatomic sites, were also associated with facial melanoma. Additional risk factors were also identified as being associated only with facial melanoma. Our results are novel as we have demonstrated that some factors known to be associated with head and neck melanoma in general may in fact be driven predominantly by facial melanomas. These findings that sub-regions of the head and neck area may not share the same risk factors add to the heterogeneous nature of the literature, and provide new avenues for future research. It is possible that factors more biological in nature drive the development of SN melanoma and influence the worse prognosis commonly observed at this site. Further work is now needed to identify new candidate risk factors for SN melanoma and disentangle the biological determinants of this anatomic sub-region.

Our results also reinforce the notion of two distinct pathways for the development of melanoma, and further suggest *IRF4* could play a role in determining pathway-specific risk, which is often marked by melanoma of different anatomic sites. A better understanding of the complex etiology of the disease and the development of a site-specific risk profile for individuals who are highly susceptible to melanoma would have significant clinical implications. Early detection is critical for improving melanoma survival and identifying the combination of risk factors associated with melanoma of specific anatomic sites, particularly those that carry a worse prognosis like SN melanoma, may help us to identify melanoma in susceptible individuals at an earlier stage. This knowledge has the potential to be translated into a more accurate risk prediction algorithm for use in clinical settings, enabling site-specific screening campaigns, and encouraging more targeted skin checks to identify melanomas earlier and improve prognosis.

ACKNOWLEDGEMENTS

The authors appreciatively acknowledge all participants for their time and involvement, as well as the Ark and the Western Australian DNA Bank at The University of Western Australia, the Western Australian Cancer Registry, and the WAMHS and GEM study teams. This work was supported by The University of Western Australia (John and Rosemary Pearman Endowment Fund scholarship to RPW), the National Health and Medical Research Council (Early Career Fellowship ID: 1121242 to SVW and Career Development Fellowship ID: 1147843 to AEC), the Cancer Institute New South Wales (Career Development Fellowship ID: 15/CDF/1-14 to

AEC), and in part by the Cancer Council of Western Australia (Capacity Building and Collaboration Grant to EKM) and the National Cancer Institute (P01CA206980 to NET and MB; R01CA233524 to NET, MB, CBB, and HAC; R01CA112243 to NET; U01CA83180 and R01CA112524 to MB; R01CA098438 to CBB; R03CA125829 and R03CA173806 to IO; P30CA016086 to the University of North Carolina and P30CA008748 to Memorial Sloan Kettering).

GEM Study Group: Coordinating Center, Memorial Sloan Kettering Cancer Center, New York, NY (USA): Marianne Berwick (PI, currently at the University of New Mexico, Albuquerque, NM), Colin Begg, Ph.D. (co-PI), Irene Orlow, Ph.D., M.S. (co-Investigator), Klaus J. Busam, M.D. (Dermatopathologist), Pampa Roy, Ph.D. (Senior Laboratory Technician), Siok Leong, M.S. (Research Assistant), Sergio Corrales-Guerrero (Senior Research Technician), Keimya Sadeghi, M.S. (Senior Laboratory Technician), Anne Reiner, M.S. (Biostatistician). University of New Mexico, Albuquerque, NM: Marianne Berwick, M.P.H., Ph.D. (PI), Li Luo, Ph.D. (Biostatistician), Tawny W. Boyce, M.P.H. (Data Manager). Study Centers: The University of Sydney and The Cancer Council New South Wales, Sydney, Australia: Anne E. Cust, Ph.D. (PI), Bruce K. Armstrong M.D. Ph.D. (former PI), Anne Kricke Ph.D., (former co-PI); Menzies Institute for Medical Research University of Tasmania, Hobart, Australia: Alison Venn (current PI), Terence Dwyer (PI, currently at University of Oxford, United Kingdom), Paul Tucker (Dermatopathologist); BC Cancer Research Centre and Department of Dermatology and Skin Science UBC, Vancouver, Canada: Richard P. Gallagher, M.A. (PI), Agnes Lai, B.A., Research Coordinator, Cancer Care Ontario, Toronto, Canada: Loraine D. Marrett, Ph.D. (PI), Lynn From, M.D. (Dermatopathologist); CPO, Center for Cancer Prevention, Torino, Italy: Roberto Zanetti, M.D (PI), Stefano Rosso, M.D., M.Sc. (co-PI); University of California, Irvine, CA: Hoda Anton-Culver, Ph.D. (PI); University of Michigan, Ann Arbor, MI: University of Michigan, Ann Arbor, MI: Stephen B. Gruber, M.D., M.P.H., Ph.D. (PI, currently at University of Southern California, Los Angeles, CA), Shu-Chen Huang, M.S., M.B.A. (co-Investigator, joint at USC-University of Michigan); University of North Carolina, Chapel Hill, NC: Nancy E. Thomas, M.D., Ph.D. (PI), Kathleen Conway, PhD (co-Investigator), David W. Ollila, M.D. (co-Investigator), Sharon N. Edmiston, BA (Research Analyst), Honglin Hao (Laboratory Specialist), Eloise Parrish, MSPH (Laboratory Specialist), Jill S. Frank, MS (Research Assistant), David C. Gibbs, B.S. (Research Assistant, currently MD/PhD candidate at Emory University, Atlanta, GA); University of Pennsylvania, Philadelphia, PA: Timothy R. Rebbeck, Ph.D. (former PI), Peter A. Kanetsky, M.P.H., Ph.D.

(PI, currently at H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL); UV data consultants: Julia Lee Taylor, Ph.D. and Sasha Madronich, Ph.D., National Centre for Atmospheric Research, Boulder, CO.

REFERENCES

1. Nikolaou V, Stratigos AJ. Emerging trends in the epidemiology of melanoma. *Br J Dermatol* **2014**;170(1):11-9.
2. Tucker MA, Goldstein AM. Melanoma etiology: where are we? *Oncogene* **2003**;22(20):3042-52.
3. Dabouz F, Barbe C, Lesage C, Le Clainche A, Arnoult G, Hibon E, et al. Clinical and histological features of head and neck melanoma: a population-based study in France. *Br J Dermatol* **2014**.
4. Lachiewicz AM, Berwick M, Wiggins CL, Thomas NE. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. *Arch Dermatol* **2008**;144(4):515-21.
5. de Giorgi V, Rossari S, Gori A, Grazzini M, Savarese I, Crocetti E, et al. The prognostic impact of the anatomical sites in the 'head and neck melanoma': scalp versus face and neck. *Melanoma Res* **2012**;22(5):402-5.
6. Ozao-Choy J, Nelson DW, Hiles J, Stern S, Yoon JL, Sim MS, et al. The prognostic importance of scalp location in primary head and neck melanoma. *J Surg Oncol* **2017**;116(3):337-43.
7. Pollack LA, Li J, Berkowitz Z, Weir HK, Wu X-C, Ajani UA, et al. Melanoma survival in the United States, 1992 to 2005. *J Am Acad Dermatol* **2011**;65(5 Suppl 1):S78-S86.
8. Tseng WH, Martinez SR. Tumor location predicts survival in cutaneous head and neck melanoma. *J Surg Res* **2011**;167(2):192-8.
9. Golger A, Young DS, Ghazarian D, Neligan PC. Epidemiological features and prognostic factors of cutaneous head and neck melanoma: a population-based study. *Arch Otolaryngol Head Neck Surg* **2007**;133(5):442-7.
10. Huismans AM, Haydu LE, Shannon KF, Quinn MJ, Saw RP, Spillane AJ, et al. Primary melanoma location on the scalp is an important risk factor for brain metastasis: a study of 1,687 patients with cutaneous head and neck melanomas. *Ann Surg Oncol* **2014**;21(12):3985-91.

11. Terakedis BE, Anker CJ, Leachman SA, Andtbacka RH, Bowen GM, Sause WT, et al. Patterns of failure and predictors of outcome in cutaneous malignant melanoma of the scalp. *J Am Acad Dermatol* **2014**;70(3):435-42.
12. Begg C, Hummer A, Mujumdar U, Armstrong B, Kricker A, Marrett L, et al. A design for cancer case-control studies using only incident case: experience with the GEM study of melanoma. *Int J Epidemiol* **2006**;35:756-64.
13. Ward SV, Cadby G, Lee A, Cole JM, Heyworth JS, Millward MJ, et al. The Western Australian Melanoma Health Study: Study design and participant characteristics. *Cancer Epidemiol* **2011**;35(5):423–31.
14. Fritz A, Percy C, Jack A, Shanmugaratnam K, Leslie S, Parkin M, et al. International Classification of Diseases for Oncology. World Health Organisation; 2013.
15. Whiteman D, Whiteman C, Green A. Childhood sun exposure as a risk factor for melanoma: A systematic review of epidemiological studies. *Cancer Causes Control* **2001**;12:69-82.
16. The Genomes Project Consortium, Auton A, Abecasis GR, Altshuler DM, Durbin RM, Abecasis GR, et al. A global reference for human genetic variation. *Nature* **2015**;526:68.
17. Orlow I, Roy P, Reiner AS, Yoo S, Patel H, Paine S, et al. Vitamin D receptor polymorphisms in patients with cutaneous melanoma. *Int J Cancer* **2012**;130(2):405-18.
18. Sham PC, Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. *Ann Hum Genet* **1995**;59(1):97-105.
19. Viechtbauer W. Conducting meta-analyses in R with the metafor package. *J Stat Softw* **2010**;36(3):1-48.
20. R-Development-Core-Team. R: A language and environment for statistical computing. Vienna, Austria, URL: <http://www.R-project.org>; R Foundation for Statistical Computing; 2008.
21. Chen Y-T, Dubrow R, Holford TR, Zheng T, Barnhill RL, Berwick M. Malignant melanoma risk factors by anatomic site: A case-control study and polychotomous logistic regression analysis. *Int J Cancer* **1996**;67(5):636-43.
22. Helsing P, Røksahm TE, Vos L, Rizvi SMH, Akslen LA, Veierød MB. Cutaneous head and neck melanoma (CHNM): A population-based study of the prognostic impact of tumor location. *J Am Acad Dermatol* **2016**;75(5):975-82.e2.
23. Shashanka R, Smitha BR. Head and neck melanoma. *ISRN Surg* **2012**;2012:948302-.

24. Siskind V, Whiteman DC, Aitken JF, Martin NG, Green AC. An analysis of risk factors for cutaneous melanoma by anatomical site (Australia). *Cancer Causes Control* **2005**;16(3):193-9.
25. Caini S, Gandini S, Sera F, Raimondi S, Fargnoli MC, Boniol M, et al. Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant. *Eur J Cancer* **2009**;45(17):3054-63.
26. Nielsen K, Masback A, Olsson H, Ingvar C. A prospective, population-based study of 40,000 women regarding host factors, UV exposure and sunbed use in relation to risk and anatomic site of cutaneous melanoma. *Int J Cancer* **2012**;131(3):706-15.
27. Whiteman D, Watt P, Purdie D, Hughes M, Hayward N, Green A. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. *J Natl Cancer Inst* **2003**;95(11):806-12.
28. Kvaskoff M, Pandeya N, Green AC, Perry S, Baxter C, Davis MB, et al. Site-specific determinants of cutaneous melanoma: a case-case comparison of patients with tumors arising on the head or trunk. *Cancer Epidemiol Biomarkers Prev* **2013**;22(12):2222-31.
29. Green A. A theory of site distribution of melanomas: Queensland, Australia. *Cancer Causes Control* **1992**;3(6):513-6.
30. Potrony M, Rebollo-Morell A, Giménez-Xavier P, Zimmer L, Puig-Butille JA, Tell-Marti G, et al. IRF4 rs12203592 functional variant and melanoma survival. *Int J Cancer* **2017**;140(8):1845-9.
31. Visser M, Palstra R-J, Kayser M. Allele-specific transcriptional regulation of IRF4 in melanocytes is mediated by chromatin looping of the intronic rs12203592 enhancer to the IRF4 promoter. *Hum Mol Genet* **2015**;24(9):2649-61.
32. Praetorius C, Grill C, Stacey Simon N, Metcalf Alexander M, Gorkin David U, Robinson Kathleen C, et al. A Polymorphism in IRF4 Affects Human Pigmentation through a Tyrosinase-Dependent MITF/TFAP2A Pathway. *Cell* **2013**;155(5):1022-33.
33. Duffy DL, Zhao ZZ, Sturm RA, Hayward NK, Martin NG, Montgomery GW. Multiple Pigmentation Gene Polymorphisms Account for a Substantial Proportion of Risk of Cutaneous Malignant Melanoma. *J Invest Dermatol* **2010**;130(2):520-8.
34. Duffy DL, Iles MM, Glass D, Zhu G, Barrett JH, Höiom V, et al. IRF4 variants have age-specific effects on nevus count and predispose to melanoma. *Am J Hum Genet* **2010**;87(1):6-16.

35. Han J, Kraft P, Nan H, Guo Q, Chen C, Qureshi A, et al. A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. *PLoS Genetics* **2008**;4(5):e1000074.
36. Lee EY, Williamson R, Watt P, Hughes MC, Green AC, Whiteman DC. Sun exposure and host phenotype as predictors of cutaneous melanoma associated with neval remnants or dermal elastosis. *Int J Cancer* **2006**;119(3):636-42.
37. Gibbs DC, Orlow I, Bramson JI, Kanetsky PA, Luo L, Kricker A, et al. Association of interferon regulatory factor-4 polymorphism rs12203592 with divergent melanoma pathways. *J Natl Cancer Inst* **2016**;108(7):djw004.
38. Smoller BR. Histologic criteria for diagnosing primary cutaneous malignant melanoma. *Mod Pathol* **2006**;19:S34.
39. Swetter SM, Boldrick JC, Jung SY, Egbert BM, Harvell JD. Increasing Incidence of Lentigo Maligna Melanoma Subtypes: Northern California and National Trends 1990–2000. *J Invest Dermatol* **2005**;125(4):685-91.
40. Whiteman D, Green A. Melanoma and sunburn. *Cancer Causes Control* **1994**;5(6):564-72.

Table 1: Demographic and pigmentary characteristics and their association with melanoma of the scalp/neck and face, compared with melanoma of other sites, in the combined Western Australian Melanoma Health Study and Genes, Environment and Melanoma Study sample (n=4480)

Characteristic		Anatomic site distributions						Association compared to other anatomic sites of melanoma ^{a,b}					
		Scalp and neck (n=293)		Face (n=460)		Other anatomic sites (n=3727)		Scalp and neck melanoma			Facial melanoma		
		n	[%]	n	[%]	n	[%]	OR	95% CI	P _{trend}	OR	95% CI	P _{trend}
Sex	Male	212	[72.4]	316	[68.7]	1992	[53.4]	1.00	(reference)		1.00	(reference)	
	Female	81	[27.6]	144	[31.3]	1735	[46.6]	0.49	0.37 - 0.64	<0.001	0.66	0.53 - 0.82	<0.001
Age (years)	<50	74	[25.3]	56	[12.2]	1138	[30.5]	1.00	(reference)		1.00	(reference)	
	50 - 59	40	[13.7]	80	[17.4]	879	[23.6]	0.60	0.40 - 0.89		1.77	1.24 - 2.55	
	60 -69	81	[27.6]	106	[23.0]	833	[22.4]	1.18	0.84 - 1.67		2.49	1.77 - 3.55	
	≥70	98	[33.4]	218	[47.4]	877	[23.5]	1.28	0.92 - 1.80	0.016	4.57	3.34 - 6.35	<0.001
Nevi ^c	None	70	[23.9]	134	[29.1]	674	[18.1]	1.00	(reference)		1.00	(reference)	
	Few/some/many	206	[70.3]	312	[67.8]	2901	[77.8]	0.66	0.49 - 0.89	0.006	0.65	0.52 - 0.83	<0.001
	Missing	17	[5.8]	14	[3.0]	152	[4.1]						
Freckling ^d	None/very few/few	238	[81.2]	381	[82.8]	3025	[81.2]	1.00	(reference)		1.00	(reference)	
	Some/many/very many	42	[14.3]	67	[14.6]	580	[15.6]	1.05	0.73 - 1.47	0.783	1.18	0.88 - 1.57	0.254
	Missing	13	[4.4]	12	[2.6]	122	[3.3]						
Hair colour index	Dark	85	[29.0]	168	[36.5]	1105	[29.6]	1.00	(reference)		1.00	(reference)	
	Light	171	[58.4]	253	[55.0]	2214	[59.4]	1.03	0.79 - 1.36		0.79	0.64 - 0.98	
	Red	33	[11.3]	30	[6.5]	365	[9.8]	1.30	0.84 - 1.97	0.338	0.65	0.42 - 0.97	0.010
	Missing	4	[1.4]	9	[2.0]	43	[1.2]						
Eye colour index	Dark	50	[17.1]	68	[14.8]	663	[17.8]	1.00	(reference)		1.00	(reference)	
	Light	241	[82.3]	388	[84.3]	3038	[81.5]	1.00	0.73 - 1.39	0.999	1.19	0.91 - 1.59	0.211
	Missing	2	[0.7]	4	[0.9]	26	[0.7]						
Skin colour	Brown/olive	25	[8.5]	42	[9.1]	406	[10.9]	1.00	(reference)		1.00	(reference)	
	Fair/very fair	265	[90.4]	417	[90.7]	3306	[88.7]	1.29	0.85 - 2.02	0.250	1.22	0.87 - 1.74	0.263
	Missing	3	[1.0]	1	[0.2]	15	[0.4]						
Burn index	No burn/mild burn	151	[51.5]	236	[51.3]	1833	[49.2]	1.00	(reference)		1.00	(reference)	
	Burn & peel/burn & blister	136	[46.4]	210	[45.7]	1837	[49.3]	0.94	0.73 - 1.20	0.616	0.99	0.80 - 1.22	0.906
	Missing	6	[2.0]	14	[3.0]	57	[1.5]						
Tan index	Moderate tan/deep tan	159	[54.3]	263	[57.2]	2111	[56.6]	1.00	(reference)		1.00	(reference)	
	Mild tan/no tan	127	[43.3]	189	[41.1]	1557	[41.8]	1.20	0.93 - 1.53	0.161	1.04	0.84 - 1.28	0.728
	Missing	7	[2.4]	8	[1.7]	59	[1.6]						
Histogloical subtype ^e	Non-lentigo maligna	234	[79.9]	261	[56.7]	3547	[95.2]	1.00	(reference)		1.00	(reference)	
	Lentigo maligna	59	[20.1]	199	[43.3]	180	[4.8]	4.67	3.28 - 6.58	<0.001	12.74	9.84 - 16.54	<0.001

Abbreviations: OR, Odds Ratio; CI, Confidence Interval

^a Logistic regression was used to estimate ORs, 95% CIs and trend P-values for scalp/neck and facial melanoma, compared to other sites. Bold type indicates P-values < 0.05.

^b Baseline adjustment for study features: sex, age at diagnosis (continuous), study centre and whether first or higher order melanoma.

^c Categories based on pictures of four bodies showing different degrees of nevi coverage.

^d Categories based on six pictures showing degree of facial freckling.

^e Including superficial spreading melanoma, nodular melanoma, spindle cell melanoma.

Table 2: Sun exposure characteristics and their associations with melanoma of the scalp/neck and face, compared with melanoma of other sites, in the combined Western Australian Melanoma Health Study and Genes, Environment and Melanoma Study sample (n=4480)

Characteristic		Anatomic site distributions						Association compared to other anatomic sites of melanoma ^{a, b}					
		Scalp and neck (n=293)		Face (n=460)		Other anatomic sites (n=3727)		Scalp and neck melanoma			Facial melanoma		
		n	[%]	n	[%]	n	[%]	OR	95% CI	P _{trend}	OR	95% CI	P _{trend}
Painful sunburns - childhood	0	105	[35.8]	193	[42.0]	1362	[36.5]	1.00	(reference)		1.00	(reference)	
	≥1	94	[32.1]	158	[34.3]	1491	[40.0]	0.79	0.60 - 1.06	0.116	0.73	0.58 - 0.92	0.007
	<i>Missing</i>	47	[16.0]	61	[13.3]	411	[11.0]						
Blistering sunburns - childhood	0	158	[53.9]	278	[60.4]	2053	[55.1]	1.00	(reference)		1.00	(reference)	
	≥1	66	[22.5]	104	[22.6]	994	[26.7]	0.80	0.59 - 1.06	0.125	0.72	0.56 - 0.92	0.008
	<i>Missing</i>	46	[15.7]	56	[12.2]	476	[12.8]						
Painful sunburns - adolescence	0	136	[46.4]	250	[54.3]	1820	[48.8]	1.00	(reference)		1.00	(reference)	
	≥1	100	[34.1]	143	[31.1]	1284	[34.5]	1.05	0.79 - 1.40	0.723	0.90	0.71 - 1.14	0.362
	<i>Missing</i>	22	[7.5]	29	[6.3]	217	[5.8]						
Blistering sunburns - adolescence	0	195	[66.6]	329	[71.5]	2512	[67.4]	1.00	(reference)		1.00	(reference)	
	≥1	62	[21.2]	78	[17.0]	734	[19.7]	0.99	0.72 - 1.35	0.964	0.85	0.64 - 1.12	0.227
	<i>Missing</i>	25	[8.5]	38	[8.3]	325	[8.7]						
Weekday sun exposure (hours) - childhood^c	Mean (SD)		2.4 (1.2)		2.4 (1.3)		2.3 (1.2)	1.01	0.90 - 1.13	0.852	1.04	0.95 - 1.13	0.384
	<i>Missing</i>		2		4		29						
Weekend sun exposure (hours) - childhood^c	Mean (SD)		5.3 (1.9)		5.2 (2.0)		5.0 (1.2)	1.02	0.96 - 1.09	0.475	1.02	0.96 - 1.07	0.548
	<i>Missing</i>		3		4		31						
Weekday sun exposure (hours) - adolescence^c	Mean (SD)		2.3 (2.4)		2.4 (2.5)		2.2 (1.2)	0.95	0.90 - 1.00	0.072	0.99	0.94 - 1.03	0.567
	<i>Missing</i>		4		3		42						
Weekend sun exposure (hours) - adolescence^c	Mean (SD)		4.5 (2.2)		4.3 (2.2)		4.2 (1.2)	0.99	0.94 - 1.06	0.852	0.97	0.93 - 1.02	0.303
	<i>Missing</i>		4		3		45						
Sun bed use (more than once)	No	113	[38.6]	160	[34.8]	1592	[42.7]	1.00	(reference)		1.00	(reference)	
	Yes	178	[60.8]	300	[65.2]	2122	[56.9]	1.15	0.82 - 1.63	0.414	1.05	0.80 - 1.41	0.717
	<i>Missing</i>	2	[0.7]	0	[0]	13	[0.3]						

Abbreviations: OR: Odds Ratio; CI: Confidence Interval

^a Logistic regression was used to estimate ORs, 95% CIs and trend P-values for scalp/neck and facial melanoma, compared with other sites. Bold type indicates P-values < 0.05.

^b Baseline adjustment for study features: sex, age at diagnosis (continuous), study centre and whether first or higher order melanoma.

^c Self-reported average sun exposure between 9am - 5pm during the warmer months.

Table 3: Association of selected melanoma risk SNPs with melanoma of the scalp/neck and face, compared with melanoma of other sites, in the combined Western Australian Melanoma Health Study and Genes, Environment and Melanoma Study sample (n=4480)

Gene/Region	SNP	Association compared to other anatomic sites of melanoma ^{a, b}					
		Scalp and neck melanoma			Facial melanoma		
		OR	95% CI	P _{trend}	OR	95% CI	P _{trend}
<i>ARNT</i>	rs7412746	1.01	0.85 - 1.20	0.925	1.01	0.88 - 1.17	0.853
<i>PARP1</i>	rs3219090	1.10	0.91 - 1.32	0.322	1.10	0.94 - 1.28	0.244
<i>NID1</i>	rs3768080	0.98	0.82 - 1.16	0.785	0.99	0.86 - 1.14	0.838
<i>TERT;CLPTM1L</i>	rs4975616	0.89	0.75 - 1.07	0.213	1.04	0.90 - 1.21	0.595
<i>SLC45A2</i>	rs35391	0.98	0.35 - 2.17	0.961	1.06	0.47 - 2.09	0.867
<i>IRF4</i>	rs12203592	1.35	1.12 - 1.63	0.002	1.29	1.10 - 1.50	0.001
<i>IRF4</i>	rs872071	0.92	0.78 - 1.09	0.348	0.99	0.86 - 1.14	0.907
<i>TYRP1</i>	rs1408799	0.97	0.80 - 1.16	0.732	0.95	0.82 - 1.11	0.531
<i>MTAP</i>	rs7023329	1.00	0.85 - 1.18	0.980	1.14	0.99 - 1.31	0.063
<i>MTAP</i>	rs10811629	1.08	0.91 - 1.28	0.356	1.13	0.98 - 1.30	0.096
<i>CCND1</i>	rs11263498	0.88	0.74 - 1.06	0.181	0.81	0.70 - 0.94	0.007
<i>TYR</i>	rs1042602	0.97	0.81 - 1.16	0.769	1.06	0.92 - 1.23	0.409
<i>TYR</i>	rs10765198	1.09	0.91 - 1.29	0.350	0.95	0.82 - 1.10	0.511
<i>OCA2</i>	rs1800407	0.93	0.69 - 1.24	0.629	0.92	0.72 - 1.17	0.507
<i>HERC2</i>	rs1129038	1.00	0.81 - 1.23	0.987	0.97	0.81 - 1.14	0.683
<i>HERC2</i>	rs12913832	1.00	0.81 - 1.22	0.995	0.97	0.82 - 1.15	0.711
<i>ASIP</i>	rs17305657	1.24	0.95 - 1.60	0.099	1.10	0.88 - 1.37	0.410
<i>ASIP</i>	rs4911414	1.10	0.92 - 1.31	0.284	0.96	0.83 - 1.11	0.577
<i>PIGU</i>	rs910873	1.14	0.88 - 1.45	0.304	0.95	0.76 - 1.18	0.647
<i>PIGU</i>	rs17305573	1.18	0.91 - 1.51	0.206	0.89	0.70 - 1.13	0.351
<i>MX2</i>	rs45430	0.86	0.71 - 1.03	0.094	0.96	0.83 - 1.12	0.599
<i>PLA2G6</i>	rs132985	1.16	0.98 - 1.37	0.093	1.05	0.91 - 1.21	0.494

Abbreviations: SNP: Single nucleotide polymorphism; OR: Odds Ratio; CI: Confidence Interval

^a Logistic regression was used to estimate the per-allele (based on the minor allele) ORs, 95% CIs and trend P-values for scalp/neck and facial melanoma, compared to other sites. Bold type indicates P-values < 0.003 (Monte-Carlo adjusted threshold to account for multiple testing).

^b Baseline adjustment for study features: sex, age at diagnosis (continuous), study centre and whether first or higher order melanoma.